Clinical
Studies
We are conducting a number of clinical studies in several therapeutic areas.
![Female doctor talking to male patient](https://www.neurocrine.com//assets/2022/10/clinical-studies-mobile.png)
Clinical studies are an essential part of the development process to determine if an investigational treatment should be approved for use in the general population.
Movement Disorders
KINECT®-HD2
A Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine* for the potential treatment of chorea in patients with Huntington disease (HD).
Therapeutic Focus
Chorea in HD
Type
Phase 3
Status
Enrolling
NBI-98854-DCP3018
A Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of valbenazine* in patients with dyskinetic cerebral palsy (DCP).
Therapeutic Focus
DCP
Type
Phase 3
Status
Enrolling
NBI-1076986
A Phase 1 study of investigational NBI-1076986 for the potential treatment of movement disorders.
Therapeutic Focus
Movement Disorders
Type
Phase 1
Status
Enrolling
Epilepsy
STEAMBOAT™
A Phase 2, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, tolerability, and pharmacokinetics of investigational NBI-827104 in pediatric patients with epileptic encephalopathy with continuous spike-and-wave during sleep (EE-CSWS).
Therapeutic Focus
EE-CSWS
Type
Phase 2
Status
Enrolling
KAYAK™
A Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of investigational NBI-921352 as an adjunctive therapy in children and young adults (2 to 21 years old) living with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE).
Therapeutic Focus
SCN8A-DEE
Type
Phase 2
Status
Enrolling
Congenital Adrenal Hyperplasia
CAHtalyst™ Pediatric
A global, registrational, Phase 3, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, and tolerability of investigational crinecerfont in children and adolescents (2 to 17 years old) with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD).
Therapeutic Focus
CAH in children & adolescents
Type
Phase 3
Status
Active; not recruiting
CAHtalyst™ Adult
A global, registrational, Phase 3, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, and tolerability of investigational crinecerfont in adults (18 years and older) with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD).
Therapeutic Focus
CAH in adults
Type
Phase 3
Status
Active; not recruiting
Neuropsychiatric Disorders
Journey™ Study
A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of valbenazine* as an add-on treatment for schizoprenia.
Therapeutic Focus
Schizophrenia
Type
Phase 3
Status
Enrolling
SAVITRI™
A Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of investigational NBI-1065845 in patients with inadequate responses to treatment in major depressive disorder (MDD).
Therapeutic Focus
MDD
Type
Phase 2
Status
Enrolling
ERUDITE™
A Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of investigational luvadaxistat for the potential treatment of cognitive symptoms of schizophrenia (CIAS).
Therapeutic Focus
CIAS
Type
Phase 2
Status
Active; not recruiting
NBI-1117568
A Phase 2, multicenter, multi-stage inpatient study to assess the efficacy, safety, tolerability, and pharmacokinetics of investigational NBI-1117568 in adults with schizophrenia.
Therapeutic Focus
Schizophrenia
Type
Phase 2
Status
Enrolling
NBI-1070770
A Phase 2 study of investigational NBI-1070770 for the treatment of major depressive disorder.
Therapeutic Focus
MDD
Type
Phase 2
Status
Enrolling
NBI-1117570
A Phase 1 study of investigational NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions.
Therapeutic Focus
Symptoms of psychosis and cognition
Type
Phase 1
Status
Enrolling
NBI-1117569
A Phase 1 study of investigational NBI-1117569 for the potential treatment of certain neurological and neuropsychiatric conditions.
Therapeutic Focus
Neurological and neuropsychiatric conditions
Type
Phase 1
Status
Enrolling
NBI-1065890
A Phase 1 study of investigational NBI-1065890 for the potential treatment of certain neurological and neuropsychiatric conditions.
Therapeutic Focus
Neurological and neuropsychiatric conditions
Type
Phase 1
Status
Enrolling
NBI-1117567
A Phase 1 study of investigational NBI-1117567 for the potential treatment of certain neurological and neuropsychiatric conditions.
Therapeutic Focus
Neurological and neuropsychiatric conditions
Type
Phase 1
Status
Enrolling
Neurocrine Biosciences has global rights unless otherwise noted. | |
* | Mitsubishi Tanabe Pharma Corporation has commercialization rights in Japan and other select Asian markets. |